Begoña Laiz-Marro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Begoña Laiz-Marro has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Jordi Tortosa-Carreres
Laboratory Department , Hospital Universitari i Politècnic La Fe , Valencia , Spain
7 shared publications - Jessica Castillo-Villalba
Neuroimmunology Research Group, Health Research Institute La Fe, Valencia, Spain
3 shared publications - Laura Cubas-Núñez
Neuroimmunology Research Group, Health Research Institute La Fe, Valencia, Spain
3 shared publications - Mónica Piqueras
Respiratory Infections, Health Research Institute La Fe (IISLAFE), 46026 Valencia, Spain
3 shared publications - Sara Carratalà-Boscà
Neuroimmunology Research Group, Health Research Institute La Fe, Valencia, Spain
3 shared publications - Bonaventura Casanova
Neuroimmunology Research Group, Health Research Institute La Fe, Valencia, Spain; Neurology Department, University and Polytechnic Hospital La Fe, Valencia, Spain
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1934
Implementation of a Laboratory-Integrated Clinical Decision Support System for CKD Screening and Progression Detection in Primary Care
Background: CKD remains substantially underdiagnosed and inadequately monitored. Objectives: To evaluate whether a laboratory-integrated CDSS enables opportunistic CKD detection and longitudinal surveillance in Primary Care via automated KDIGO stratification and progression detection. Methods: We implemented a CDSS embedded within the laboratory information system at Hospital Universitari i Politècnic La Fe, a tertiary university hospital in València, Spain. A one-time baseline profile screened patients with diabetes, hypertension, or age 60–80 years without documented advanced CKD, while a follow-up profile targeted patients with advanced CKD or those previously assessed by baseline screening. Both profiles applied KDIGO risk stratification and automated detection of renal and albuminuric progression based on predefined criteria, classifying each patient into one of three action categories: no CKD or low-risk requiring no action; CKD requiring Primary Care monitoring; or CKD meeting criteria for automated nephrology referral. Missed opportunities for albuminuria monitoring and economic impact of the intervention were evaluated. Results: During a 4-month period, the CDSS processed 10,733 requests, of which 10,414 were evaluable. No further action was required in 8661 patients (83.2%), monitoring was recommended in 1591 (15.3%), and nephrology referral was triggered in 162 (1.6%). Among 82 patients with albuminuric progression, 39% had not undergone ACR testing for more than two years despite ongoing Primary Care contact. Following implementation, ACR testing increased by 15.0% compared with the previous year, resulting in an additional analytical cost of EUR 1550.54. Conclusions: The CDSS enabled systematic CKD detection and surveillance in Primary Care, identifying silent renal and albuminuric progression and supporting nephrology referral at minimal cost.
- 28 August 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1934
Open AccessImplementation of a Laboratory-Integrated Clinical Decision Support System for CKD Screening and Progression Detection in Primary Care
Background: CKD remains substantially underdiagnosed and inadequately monitored. Objectives: To evaluate whether a laboratory-integrated CDSS enables opportunistic CKD detection and longitudinal surveillance in Primary Care via automated KDIGO stratification and progression detection. Methods: We implemented a CDSS embedded within the laboratory information system at Hospital Universitari i Politècnic La Fe, a tertiary university hospital in València, Spain. A one-time baseline profile screened patients with diabetes, hypertension, or age 60–80 years without documented advanced CKD, while a follow-up profile targeted patients with advanced CKD or those previously assessed by baseline screening. Both profiles applied KDIGO risk stratification and automated detection of renal and albuminuric progression based on predefined criteria, classifying each patient into one of three action categories: no CKD or low-risk requiring no action; CKD requiring Primary Care monitoring; or CKD meeting criteria for automated nephrology referral. Missed opportunities for albuminuria monitoring and economic impact of the intervention were evaluated. Results: During a 4-month period, the CDSS processed 10,733 requests, of which 10,414 were evaluable. No further action was required in 8661 patients (83.2%), monitoring was recommended in 1591 (15.3%), and nephrology referral was triggered in 162 (1.6%). Among 82 patients with albuminuric progression, 39% had not undergone ACR testing for more than two years despite ongoing Primary Care contact. Following implementation, ACR testing increased by 15.0% compared with the previous year, resulting in an additional analytical cost of EUR 1550.54. Conclusions: The CDSS enabled systematic CKD detection and surveillance in Primary Care, identifying silent renal and albuminuric progression and supporting nephrology referral at minimal cost.
- 6 March 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 587, 120943
A laboratory-driven clinical decision support system algorithm for personalized and automated cardiovascular risk stratification in primary care patients.
- 6 March 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 587, 120943
A laboratory-driven clinical decision support system algorithm for personalized and automated cardiovascular risk stratification in primary care patients.
- Open Access
- 8 December 2025
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 7 (2) , 148-152
An algorithm to predict intrathecal IgM synthesis in multiple sclerosis patients: optimizing the use of oligoclonal band testing
Objectives: We aimed to develop a simple, cost-effective algorithm to predict the presence of oligoclonal IgM bands (OCMB) in patients with multiple sclerosis (MS), using surrogate markers such as the IgM Index (IgMi) and the Free Kappa Light Chains Index (FKLCi), with the aim of reducing the need for OCMB testing while maintaining high diagnostic accuracy. Methods: A retrospective study was conducted using paired serum and cerebrospinal fluid samples from patients diagnosed with MS at disease onset at Hospital Universitari i Politècnic La Fe. Receiver operating characteristic (ROC) curve analyses were performed for IgMi and FKLCi to evaluate their ability to predict OCMB positivity. Several combinations of cutoff values prioritizing high specificity and positive predictive value (PPV) were tested, and the best-performing threshold combination was selected. Results: A total of 97 patients were included. The optimal model defined OCMB positivity as having either IgMi≥0.2 or FKLCi≥250. Applying this algorithm reduced the need for OCMB testing by 33 %, while achieving a specificity of 90 % and a PPV of 85 %. Conclusions: IgMi and FKLCi may serve as reliable predictors of OCMB positivity in MS, potentially reducing unnecessary testing and laboratory workload.
- 8 December 2025
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 7 (2) , 148-152
Open AccessAn algorithm to predict intrathecal IgM synthesis in multiple sclerosis patients: optimizing the use of oligoclonal band testing
Objectives: We aimed to develop a simple, cost-effective algorithm to predict the presence of oligoclonal IgM bands (OCMB) in patients with multiple sclerosis (MS), using surrogate markers such as the IgM Index (IgMi) and the Free Kappa Light Chains Index (FKLCi), with the aim of reducing the need for OCMB testing while maintaining high diagnostic accuracy. Methods: A retrospective study was conducted using paired serum and cerebrospinal fluid samples from patients diagnosed with MS at disease onset at Hospital Universitari i Politècnic La Fe. Receiver operating characteristic (ROC) curve analyses were performed for IgMi and FKLCi to evaluate their ability to predict OCMB positivity. Several combinations of cutoff values prioritizing high specificity and positive predictive value (PPV) were tested, and the best-performing threshold combination was selected. Results: A total of 97 patients were included. The optimal model defined OCMB positivity as having either IgMi≥0.2 or FKLCi≥250. Applying this algorithm reduced the need for OCMB testing by 33 %, while achieving a specificity of 90 % and a PPV of 85 %. Conclusions: IgMi and FKLCi may serve as reliable predictors of OCMB positivity in MS, potentially reducing unnecessary testing and laboratory workload.
- 23 September 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (2) , 845-853
Renal function’s impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis
Background sNfL, a promising biomarker for neuroaxonal damage in Multiple Sclerosis (MS), requires cautious interpretation due to several comorbidity influences. Objectives To investigate the impact of renal function on sNfL levels in MS patients. Methods This retrospective study stratified patients by MS clinical phenotype, acute inflammatory activity (AIA) status—defined as relapse or gadolinium-enhancing lesions within 90 days of sample collection—renal function, assessed by estimated glomerular filtration rate (eGFR), and age (< 40 years, 40–60 years, > 60 years). Comparative analysis of sNfL levels across these groups was performed. The sNfL-eGFR relationship was examined using linear and non-linear regression models, with the best fit determined by R2 and the F estimator. Results Data from 2933 determinations across 800 patients were analyzed. Patients with renal insufficiency (RI) (eGFR < 60 mL/min/1.73 m2) and mild renal impairment (MDRF) (eGFR 60–90 mL/min/1.73 m2) showed significantly higher sNfL levels compared to those with normal renal function, a pattern also observed in age groups 40 years and older. No significant differences were found between MDRF patients and those with AIA. Among RI patients, no differences in sNfL levels were observed between relapsing-remitting and progressive MS phenotypes. A regression S-Curve model was identified as the best fit, illustrating a marked increase in sNfL levels beginning at an eGFR of approximately 75 mL/min/1.73 m2. Discussion Caution is advised when interpreting sNfL levels for monitoring MS in patients with impaired renal function.
- 23 September 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (2) , 845-853
Renal function’s impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis
Background sNfL, a promising biomarker for neuroaxonal damage in Multiple Sclerosis (MS), requires cautious interpretation due to several comorbidity influences. Objectives To investigate the impact of renal function on sNfL levels in MS patients. Methods This retrospective study stratified patients by MS clinical phenotype, acute inflammatory activity (AIA) status—defined as relapse or gadolinium-enhancing lesions within 90 days of sample collection—renal function, assessed by estimated glomerular filtration rate (eGFR), and age (< 40 years, 40–60 years, > 60 years). Comparative analysis of sNfL levels across these groups was performed. The sNfL-eGFR relationship was examined using linear and non-linear regression models, with the best fit determined by R2 and the F estimator. Results Data from 2933 determinations across 800 patients were analyzed. Patients with renal insufficiency (RI) (eGFR < 60 mL/min/1.73 m2) and mild renal impairment (MDRF) (eGFR 60–90 mL/min/1.73 m2) showed significantly higher sNfL levels compared to those with normal renal function, a pattern also observed in age groups 40 years and older. No significant differences were found between MDRF patients and those with AIA. Among RI patients, no differences in sNfL levels were observed between relapsing-remitting and progressive MS phenotypes. A regression S-Curve model was identified as the best fit, illustrating a marked increase in sNfL levels beginning at an eGFR of approximately 75 mL/min/1.73 m2. Discussion Caution is advised when interpreting sNfL levels for monitoring MS in patients with impaired renal function.
- 24 December 2023
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 108 (3) , 116167
Evaluating the diagnostic performance of Liaison® chemiluminescence assay as screening tool for detection of acute Epstein-Barr infection: A comparative study
- 24 December 2023
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 108 (3) , 116167
Evaluating the diagnostic performance of Liaison® chemiluminescence assay as screening tool for detection of acute Epstein-Barr infection: A comparative study
- Open Access
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital
The establishment of precision medicine in cancer patients requires the study of several biomarkers. Single-gene testing approaches are limited by sample availability and turnaround time. Next generation sequencing (NGS) provides an alternative for detecting genetic alterations in several genes with low sample requirements. Here we show the implementation to routine diagnostics of a NGS assay under International Organization for Standardization (UNE-EN ISO 15189:2013) accreditation. For this purpose, 106 non-small cell lung cancer (NSCLC) and 102 metastatic colorectal cancer (mCRC) specimens were selected for NGS analysis with Oncomine Solid Tumor (ThermoFisher). In NSCLC the most prevalently mutated gene was TP53 (49%), followed by KRAS (31%) and EGFR (13%); in mCRC, TP53 (50%), KRAS (48%) and PIK3CA (16%) were the most frequently mutated genes. Moreover, NGS identified actionable genetic alterations in 58% of NSCLC patients, and 49% of mCRC patients did not harbor primary resistance mechanisms to anti-EGFR treatment. Validation with conventional approaches showed an overall agreement >90%. Turnaround time and cost analysis revealed that NGS implementation is feasible in the public healthcare context. Therefore, NGS is a multiplexed molecular diagnostic tool able to overcome the limitations of current molecular diagnosis in advanced cancer, allowing an improved and economically sustainable molecular profiling.
Open AccessDevelopment, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital
The establishment of precision medicine in cancer patients requires the study of several biomarkers. Single-gene testing approaches are limited by sample availability and turnaround time. Next generation sequencing (NGS) provides an alternative for detecting genetic alterations in several genes with low sample requirements. Here we show the implementation to routine diagnostics of a NGS assay under International Organization for Standardization (UNE-EN ISO 15189:2013) accreditation. For this purpose, 106 non-small cell lung cancer (NSCLC) and 102 metastatic colorectal cancer (mCRC) specimens were selected for NGS analysis with Oncomine Solid Tumor (ThermoFisher). In NSCLC the most prevalently mutated gene was TP53 (49%), followed by KRAS (31%) and EGFR (13%); in mCRC, TP53 (50%), KRAS (48%) and PIK3CA (16%) were the most frequently mutated genes. Moreover, NGS identified actionable genetic alterations in 58% of NSCLC patients, and 49% of mCRC patients did not harbor primary resistance mechanisms to anti-EGFR treatment. Validation with conventional approaches showed an overall agreement >90%. Turnaround time and cost analysis revealed that NGS implementation is feasible in the public healthcare context. Therefore, NGS is a multiplexed molecular diagnostic tool able to overcome the limitations of current molecular diagnosis in advanced cancer, allowing an improved and economically sustainable molecular profiling.